Clinical Trial

A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia

Study acronym: AsterA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-11.
Status change: Not Yet Recruiting → Recruiting 2026-04-01
Trial Details
NCT Number NCT06368414
Lead Sponsor Korean Society of Hematology
Conditions Chronic Myeloid Leukemia, Chronic Phase
Enrollment 69 participants
Start Date 2024-03-11
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-02